Is the dog owner at fault? Or the little girl, or the airline? It turns out there’s a really easy answer.

Bargain stock hunters have honed in their attention of late on shares of Puma Biotechnology, Inc. (NYSE:PBYI). The stock is currently valued at $68.25 after moving 3.17% in the most recent session and 0.22% over the past 5 trading days. Given that the stock is priced cheaply, let’s take a look and see if …

Digital marketing blogs may be numerous, but I find them still to be critical. I’ve been in digital marketing for over 20 years, and the only way you can stay relevant that long is to read A LOT. In digital marketing, if you don’t learn, you die. Period.

Members of the Convince & Convert team all have their own reading lists, based on their interests and their topical expertise. Together, we read nearly close to 200 online publications routinely.

Believe it or not, we keep up with blogs by a familiar and comfortable (for me) method: email. I subscribe via email and read (or at least scan) nearly 50 blogs that way. It’s actually far more than that because several of the sources I devour are actually email aggregators that pull the best posts from many, many blogs. I find that gives me the best coverage.

I recently went through my email for a week and put together this list of the 30 top digital marketing blogs and subscriptions that I consume regularly. If yours isn’t on this list, it doesn’t mean I don’t read or don’t subscribe. I just don’t read it as routinely as I do these others.

Please add your own suggestions in the comments for digital marketing resources I may have overlooked. I’m eager to see which you read, as well.

In digital marketing, if you don’t learn, you die. Period.
Click To Tweet

Buffer

This blog has gotten hugely popular in a short period of time because the content is fascinating, topical, and useful. Proud investor in this company, am I.

Cassandra Daily

If it’s not #trending, they don’t write about it. Subscribing is like having a focus group of teenagers that you don’t have to feed.

Contently Content Strategist

I’m really impressed with these guys. Solid info every day for the advanced content marketer.

Content Marketing Institute

The powerhouse of the content marketing industry. Strong information and insights, delivered daily. Great job by the CMI editorial team for keeping the quality consistently high on this multi-author blog.

Convince & Convert

Hey, that’s us! I only write one post a week (in addition to a weekly newsletter, Convince & Convert ON), so I definitely read Convince & Convert every day. Subscribe via email here.

Copyblogger

One of the originals, and still one of the best. A must-read, in my estimation. I owe these guys a huge debt, too, because they’ve helped me a lot with my own blog.

CoSchedule

Smart and purposeful content always wins, and CoSchedule does this as well as any of the top content marketing blogs.

The Daily Carnage

Curated marketing news that is handpicked by the Carney team and delivered with just enough snark to ensure it’s opened daily.

Duct Tape Marketing

From John Jantsch and occasional guest contributors, everything that gets published here is worth examining. We work mostly with medium and large businesses at Convince & Convert, but I still learn a lot from Duct Tape and their scrappy, small biz sensibilities.

Econsultancy

Solid, broad-based digital marketing coverage with a research bent. Very strong in global perspectives and trends, too.

GatherContent Blog

In addition to having a terrific platform, GatherContent has also crafted a highly informative blog. It features posts from GatherContent’s own contributors, plus guests posts from experienced content creators, content strategists, content marketers, and more. They’re giving an amazing amount of strategic information away.

{grow}

From my friend the author, speaker, and college professor Mark Schaefer and a good crew of guest writers. {Grow} is a place to find conversations about topics that aren’t covered in the more news-oriented blogs. Also a great example of a multi-author blog that somehow maintains a consistent editorial voice.

Hubspot

Remarkable volume of useful content. Essentially defined what a B2B blog could (and should be). These guys live and breathe Youtility (which is why they are mentioned in my book).

Hootsuite Blog

The Hootsuite Blog is a fantastic example of what it looks like to provide real value and relevance through content. Yes, the blog leans more toward social updates and how-tos, but it also has a mix of everything you could need when it comes to digital strategy advice and insights.

Ignite Social Media

I don’t read that many blogs written by a single agency, but Jim Tobin and the crew at Ignite seem to consistently come up with interesting approaches that I don’t see everywhere else. Bravo! Jim’s book Earn It, Don’t Buy It is full of TRUTH, too. (I got to write the foreword).

MediaReDef

Must-read for media observers. A delicious, curated mix of tech and pop culture. Great trend watching.

PR Daily News

From Ragan, a nice aggregation of posts of interest to public relations folks. Curated from other sources, and some original content.

PSFK

Maybe my favorite email to receive each day (other than Quartz, which didn’t make this list because it’s not about digital marketing). PSFK is like Willy Wonka marketing. Amazing case studies and super interesting experiments from around the world. I find a TON of my Youtility examples for keynote speeches from PSFK.

Readwrite

My preferred tech news, geek, gadget site. Not strictly digital marketing per se, but terrific at keeping me up on broader tech and social media issues.

Six Pixels of Separation

I’ll never be as smart as Mitch Joel, or as prolific. Thoughtful brilliance flows on this blog like water from a tap. The wide topical array makes it such that not every post is for every reader, but stick with Mitch, and you’re guaranteed to receive something worth your attention at regular intervals.

Social Media Examiner

Outstanding tactical coverage of all things social media, from Mike Stelzner and his excellent team. Brings the best of Social Media Marketing World to your inbox all year long.

Social Media Explorer

Founded by my pal Jason Falls, this is a thinking person’s blog of social media and digital marketing issues.

Social Media Today

A powerhouse aggregator site that has more and more content written specifically for it, too. Noise-to-signal ratio can be a little high, but frequently you’ll find interesting concepts, and it’s a very good source of fresh voices.

SocialPro Daily

From Adweek, this daily digest covers the social webs from breaking news to how-to posts. If you only check one source to keep up with the heartbeat of social media, this is a best bet.

Spin Sucks

Outstanding blog for PR folks, with a side order of content marketing and social media. Led by rockstar Gini Dietrich, with help from a great cast of guest writers. Incredibly active community too, similar to {Grow} and GatherContent.

Statista

Info-junkies like me will never tire of discovering new or useful research and stats to plug into blog posts and speaking presentations. Statista sends a Chart of the Day infographic to your email, and offers a wealth of free (in addition to paid) data and infographics on the website.

Think with Google

While not a “traditional blog,” this resource center makes my UX-loving heart happy. With insights and mind-blowing studies galore, Think with Google is a wonderful cross-section of content, design, UX, CX, marketing, and more. It’s an absolute must-read for everyone, no matter what industry or role you work within.

TopRank

Outstanding coverage of content marketing, search marketing, research, and interviews from Lee Odden and his team. Popular, and deservedly so.

Uberflip

Content experience is the name of this game, in both thematics and UX. Uberflip’s content hub mixes short videos with podcast episodes and traditional blog posts. Bonus: the meta experience of getting Uberflip’s best thinking on their own Uberflip hub.

Yext

When everyone, including Facebook, is shifting attention back to local community and location, expect marketing advice to follow. My friend Jeff Rohrs and the team at Yext are one step ahead here providing sound advice for SMB and B2C marketers.

[Read More …]

With the Olympic Games concluding this week in South Korea, the pomp and circumstances in Pyeongchang are certainly emblematic of the country’s place as an influencer on the global stage. However, the country has focused on more than winter sports these last few years. They have also developed a golden biotech industry focused on strong commercialization and global partnerships. With roughly 5% of the country’s GDP spent on R&D, the industry breakdown consists of 34% in the human health.

Over the past 25 years, multi-ministerial coordination and the realignment of industrial systems to facilitate R&D have bolstered the country to be a leading developer in the region. The Korean government designated biotechnology as a key component of the country’s development strategy in the early 1980s. With the support of the Ministry of Science and Technology, traditional manufacturing and research practices transitioned to focus on more advanced technologies. With this new priority, legislation supporting innovation and biotechnology flourished. The government’s passage of the Genetic Engineering Promotion Law in 1983, known today as the Biotechnology Promotion Law, reinforced South Korea’s strong foundation for the biosciences developments to come.

However, it was not just government support that formed the industry’s solid foundation. The establishment of research-based innovative associations in the 1990s, reinforced the strength of the growing industry. With associations such as Korean Genetic Engineering Research Association, known today as Korea Biotechnology Research Association (KBRA), and other institutions such as Korea Research Institute of Bioscience & Biotechnology, Bioindustry Association of Korea (BAK), and Korea Bio Venture Association (KoBioVen) paving the way, South Korea set out to make a big impact. In 2008, these three major Korean biotech associations joined forces, founding a new larger united association known as the Korea Biotechnology Industry Organization (Korea BIO) that supports both the bio-industry community and government.

Thriving academic institutions and an increased commitment to higher education also play a critical role in South Korea’s race to become a major player in the biotech field. South Korea is among the highest spenders on higher education of the Organization for Economic Co-operation and Development (OECD). The country also yields among the region’s top performers in mathematics, reading, and science- specifically in the life sciences industry. With over 5% of the country’s GDP spent on education in advanced degrees, South Korea’s education infrastructure has proven to take care of its own. Fostering an education ecosystem that privileges life science development has encouraged innovative life science breakthroughs.

The symbiotic relationship between government, local associations, and educational institutions has fueled the country’s engine for biosciences development. With the cooperation of these three forces, South Korea’s national R&D expenditure in biotechnology grew nearly 40-fold to over $311 million from the 1980s to mid-1990s.

But nothing was a bigger turning point in South Korea’s biotech history than The Basic Plan for the Promotion of Biotechnology in 1994. Despite its name, this plan was anything but basic. This national biotechnology plan shifted the tide for the country’s competitive edge. Since putting forth the Basic Plan for the Promotion of Biotechnology, government investment has increased at an average rate of over 24% annually until 2008.

This significant investment in R&D yielded powerful results. By 2004, there were over 500 South Korean companies using biotechnology in their businesses. Within these companies, there also was an interest to shift from producing generic branded drugs to increased focus on new drug discovery.

Government investment only continued to intensify moving forward. With over $5 billion invested in the industry infrastructure from 2004-2007, the country moved to rank 7^th among 59 countries and regions in the 2007 global competitiveness ranks by the International Institute for Management and Development (IMD). Investment grew even further in 2005 with the government investing an addition $1.4 billion into biotechnology.

Just when we thought there couldn’t be more investment, in 2006, the South Korean government established Bio-Vision 2016, which set the goal of making the country a global biotechnology leader. With goals to strengthen multi-ministerial coordination, develop advanced industrial infrastructure, promote a culture of research integrity and bioethics, and achieve innovative breakthroughs, the bar was set high. But with investment in biotechnology led by six Korean Ministries, including that of Education, Science and Technology; Knowledge Economy; Health and Welfare; Food, Agriculture, Forestry; Environment; and Land, Transport & Maritime Affairs, the country was well equipped to meet those goals.

The benefits of Bio-Vision 2016 were immediate. Within a year, the country’s Technology Strength (TS) index ranking improved to no. 13 in 2007, showing immediate improvement from no. 17 between 1998 and 2001. Effects of the policy also shifted industry towards regenerative medicine research, growing their medical devices industry, and expanding R&D capacity.

In March 2012, the U.S.-Korea Free Trade Agreement (KORUS FTA) was established, and with it both countries agreed to provisions to facilitate high-quality health care and improve access to safe and effective innovative and generic pharmaceutical products. Implementation of KORUS has led to various policy improvements, including regulatory data protection and intellectual property enforcement, although there remain strong concerns on South Korea’s implementation of its intellectual property rights and pricing and reimbursement commitments.

With the strengthening industrial capacity and growing support from local associations, South Korea developed a balanced regional and national system that supported biotech clusters throughout the country. These established hubs became epicenters of innovation with a goal of making regional economic development self-sustaining and self-reliant.

This environment propelled the biotech industry to what it is today. South Korea is one of the most aggressive countries in the region for the development of biosimilars, with the government setting an ambitious goal of providing 22% of global biosimilars supply by 2020. That said, ask anyone in the pharma business in South Korea what’s next and the overwhelming answer would be: expanding global partnerships and making the country a global hub of biotechnology.

BIO continues to champion the progress being made in Asia and recognizes that global collaborations are critical to not only South Korea’s success, but also those of global stakeholders seeking to find investment and licensing partners in country. To foster those cross-border partnerships, BIO is hosting its 15^th annual BIO Asia International Conference on March 19-20, 2018 in Tokyo, Japan. This year, we will feature a dedicated session entitled Market Outlook-Investor Priorities and Structuring Cross-Border Financing and look forward to welcoming Korean biotechs including:

• Eone-Diagnomics Genome Center
• 1ST Biotherapeutics, Inc.
• OliX Pharmaceuticals
• MyGenomeBox Co.,Ltd
• SIWON Intellectual Property Firm
• Y-Biologics Inc.
• Gyeongsang National University
• SPARK Korea, Korea University
• Chungnam National University
• Daewoong Pharmaceutical Co., Ltd.
• NGeneBio Co., Ltd.
• Samsung BioLogics
• IMGT Corp.
• Konkuk University
• Standigm
• Pharos I&BT Co., Ltd
• Kolon Life Science

To learn more about this exclusive partnering forum focused on doing business in the current Asia-Pacific business and policy environments, visit www.bio.org/asia.

South Korea’s rich history of support for the biotech field provides the country a favorable platform to address the challenges ahead. Accordingly, we anxiously watch as South Korea continues to help us make biotech history!

Over the last decade, I’ve become increasingly conscious of maintaining my cardiovascular health, making dietary changes and keeping my blood pressure and cholesterol levels in check. Heart disease is preventable and taking sensible steps can help a person dodge the number one killer in our country.

It’s true that heart disease kills more Americans than any other cause, including cancer, and it claims more lives than strokes, Alzheimer’s, diabetes, influenza, pneumonia and accidents combined.

One in four U.S. deaths is attributable to heart disease, but at least 200,000 of those could be prevented each year, according to the Centers for Disease Control and Prevention (CDC).

The CDC says high blood pressure, high blood cholesterol and smoking are the three leading causes of heart disease. In addition to putting down the cigarettes, one of the best ways to stay heart-healthy is to eat food low in trans-fat, saturated fat, sodium and sugar. Also, everyone should strive for at least 2 ½ hours of physical activity to get you heart pumping, according to the National Heart, Lung and Blood Institute.

Heart disease, of course, can lead to heart attacks. Life-threatening coronary events often seem to come on suddenly and unexpectedly, but the cardiovascular disease that produces heart attacks is usually the product of a gradual buildup. That’s why it’s important – and potentially life-saving – to know the warning signs of a heart attack.

You may have heard stories of people who suffered a heart attack but didn’t know as it was occurring. That’s because some symptoms are not readily associated with the heart.  Almost half of sudden cardiac deaths occur outside a hospital, according to the CDC, suggesting many people may not be acting on early warning signs. The more time that goes by without seeking help from a medical professional, the greater the damage can be to the heart muscle. Doctors says it’s crucial to get to the hospital within 90 minutes of a heart attack to ensure blood flow is restored to the heart.

One classic symptom of a heart attack is pain radiating down the left side of the body.  Feeling dizzy or lightheaded – along with chest discomfort – are other potential indicators. However, symptoms of a heart attack can differ based on gender. Women sometimes describe severe exhaustion, fainting spells and headaches, while men can report nausea, indigestion, heartburn and even stomach pain. Other signs of a possible heart attack include swollen legs, sweating, a coughing fit, and feeling fatigued after doing something you had no problem with in the past, such as climbing stairs.

High cholesterol levels can increase the risk of heart attack. When there is a high amount of cholesterol in our bloodstream, an excess amount can find its way into the arteries. Eventually, it can harden into plaque causing atherosclerosis, which has the potential to prevent blood flow to the heart.

Encouragingly, the death rate from heart disease has fallen by 39 percent over the past decade, and biomedical innovation is a big reason why. In a single year in America, cholesterol-lowering statins save 40,000 lives, prevent 60,000 heart attacks, and avert 22,000 strokes. More than one in five Americans between the ages of 40 and 75 – myself included – currently take a statin to lower their cholesterol and risk of heart attack or stroke.

Researchers are also studying how reducing inflammation can reduce the risk of a heart attack. This past summer Novartis made a splash when the results of a Phase III study revealed that targeting inflammation with a drug called canakinumab reduced major adverse cardiovascular events in people with a prior heart attack.

“The results are exciting because we now have clear evidence that in addition to lowering cholesterol, targeting inflammation reduces patients’ risk of cardiovascular disease, and perhaps even lung cancer,” said Dr. Paul Ridker, who chaired the study.

“Bad” cholesterol, known as LDL, is still the single most important risk factor for developing heart disease. In the last two years, statins have been paired with a new medication called PCSK9 inhibitors that can lower cholesterol by as much as 60 percent.  They target a known protein that destroys LDL receptors, which sit on the surface of liver cells and remove cholesterol from the blood. High-intensity statins reduce cholesterol by up to 50 percent, but if a PCSK9 inhibitor is added, cholesterol levels are reduced even more.

February is American Heart Month. As the biotechnology sector continues to explore and pioneer new approaches in the fight against heart disease, be sure to encourage your loved ones to take control of their diets, medication management and physical activity to increase their odds of living longer, happier and healthier lives.

It is an underreported fact that the time it takes for a generic medicine to come to market has remained steady at approximately 13.5 years for over two decades. And, once entering the market, generics are acquiring greater market share, faster than ever before.

That’s why BIO is releasing its a new infographic, which highlights the highly successful effects of the Hatch-Waxman Act and the role it has played in balancing innovation and competition, as Congress intended.

BIO supports continued FDA initiatives to improve first-cycle generic approval rates, as this problem is the biggest barrier to more generic entry.

submitted by /u/Semi-ColonNightmare
[link] [comments]

As biotechnology continues to drive advancement in the way we grow and consume food, consumer skepticism around biotechnology remains steady. As I alluded to in Science Over Fiction: GMOS for Public Good, consumer skepticism is largely derived from misconceptions around the science behind biotechnology.

For example, take the following survey results as noted in a piece from Agri-Pulse titled Are consumer ready to accept gene editing?

A Michigan State University Food Literacy and Engagement Poll asked 1,059 U.S. adults last summer, for example, if this statement is true: “Genetically modified foods have genes and non-genetically modified foods do not,” and 37 percent agreed, showing that many people just don’t know what genes or GMOs are.

More concerning, however, are the results from another survey mentioned in the piece, in which Americans were asked if they want mandatory labeling of DNA in foods.

The result: 80 percent said yes. Obviously, those respondents did not understand that DNA (deoxyribonucleic acid) is an essential part of all living organisms – organic, non-GMO or GMO.

What’s intriguing, however, is the fact that most people (59 percent) “expressed at least some support for human genome editing to treat human medical conditions or restore health.”

This mix of opinions affirm the notion that many perceptions about biotechnology and food are based on misunderstanding and fear. As we touched on in When Food Companies Use Lies (and Children!) to Fool Consumers, the organic industry has found success in generating fear among the public when it comes to biotechnology in food. But, when consumers start to think about biotechnology’s benefit to their own health, perceptions seem to change.

Gene editing carries many of the same promises that gene modification does, but will consumers fall victim to fearmongering or will they begin to understand the science behind it and accept this promising technology?

Read the full piece here.

Puma Biotechnology logo Dupont Capital Management Corp purchased a new stake in Puma Biotechnology Inc (NASDAQ:PBYI) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 5,977 shares of the …